Loading Pathway...
Error: Pathway image not found.
Hide
Pathway Description
Bevantolol Action Pathway
Homo sapiens
Drug Action Pathway
Bevantolol hydrocholride, also known as bevantolol, is a cardioselective beta blocker prescribed to treat angina pectoris and hypertension. Bevantolol is an antagonist of beta-1 adrenoreceptors to block the G protein signalling cascade and inhibit epinephrine induced sympathetic activation such as, increased heart rate. It does not have intrinsic sympathomimetic activity therefore does not stimulate beta-adrenergic receptors. This results in a decrease in preload and blood pressure.
References
Bevantolol Pathway References
Vaughan Williams EM: Bevantolol: a beta-1 adrenoceptor antagonist with unique additional actions. J Clin Pharmacol. 1987 Jul;27(7):450-60.
Pubmed: 2888789
Kaplan HR: Bevantolol hydrochloride--preclinical pharmacologic profile. Angiology. 1986 Mar;37(3 Pt 2):254-62. doi: 10.1177/000331978603700319.
Pubmed: 2871786
Jaillon P: Relevance of intrinsic sympathomimetic activity for beta blockers. Am J Cardiol. 1990 Sep 25;66(9):21C-23C.
Pubmed: 1977302
Striated Muscle Contraction References
Cooke R: The sliding filament model: 1972-2004. J Gen Physiol. 2004 Jun;123(6):643-56. doi: 10.1085/jgp.200409089.
Pubmed: 15173218
Szent-Gyorgyi A: The mechanism of muscle contraction. Proc Natl Acad Sci U S A. 1974 Sep;71(9):3343-4.
Pubmed: 4610574
Kuo IY, Ehrlich BE: Signaling in muscle contraction. Cold Spring Harb Perspect Biol. 2015 Feb 2;7(2):a006023. doi: 10.1101/cshperspect.a006023.
Pubmed: 25646377
Highlighted elements will appear in red.
Highlight Compounds
Highlight Proteins
Enter relative concentration values (without units). Elements will be highlighted in a color gradient where red = lowest concentration and green = highest concentration. For the best results, view the pathway in Black and White.
Visualize Compound Data
Visualize Protein Data
Settings